Skin Cancer

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application (sNDA) for the use of Tafinlar (dabrafenib) combined with Mekinist (trametinib) as an adjuvant treatment for patients with BRAFV600E– or V600K–positive stage 3 melanoma following complete resection.

Breast cancer and melanoma survivor shares coping strategies for the holidays.

The FDA has approved Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease, based on findings from the phase 3 CheckMate-238 trial.

Jim Kelly, NFL Hall of Famer, discusses how much a smile or a kind word can mean to someone with cancer – and he knows from experience.

It was a hard call to make. It felt like choosing to step into the mud—again. Revisit cancer? Seriously? Why?

One of our valued community members, Jen Sotham, passed away on Nov. 9. Jen was diagnosed with metastatic melanoma in 2014, but that did not prevent her from living out her dreams and having her voice heard through film, blogging, a TED talk and contributing to CURE® — both in print and on the web.

Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) improved response rates in patients with melanoma, but not without some severe side effects.

Two-time cancer survivor struggles with a different loss than cancer this holiday season.

Are you trying to get ready for the holidays in addition to being newly diagnosed with cancer, receiving active treatment or coping with survivorship? It’s not an easy task.

A two-time cancer survivor shares strategies that have helped her over the years with healthy eating habits and movement.

In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Nearly a third of tanning salons surveyed were not compliant with their state laws.

An immunotherapy finally gives doctors an approved weapon to fight Merkel cell carcinoma, a rare and still mysterious skin cancer.

It isn't always so "normal," is it?

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the adjuvant treatment of patients who have stage 3 melanoma and a BRAF V600 mutation, after they have already had a complete resection.

Research into combination approaches now focuses on using three anti–PD-1 therapies and new checkpoints, such as IDO.

The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

The longest response rate lasted six months.

Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according to findings presented at the 2017 World Congress of Melanoma.

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

Intralesional therapies – those delivered directly to the tumor site – used in conjunction with checkpoint inhibitors have shown improvements to the treatment of people with melanoma, says Robert Andtbacka, M.D., in a presentation at the 2017 World Congress of Melanoma.

Members of the public can submit comments to the U.S. Preventive Services Task Force (USPSTF) on its draft recommendation statement on sun protection until Nov. 6, 2017.

Opdivo (nivolumab) was granted a priority review to a supplemental biologics license application (sBLA) to treat patients with melanoma who have a high risk of disease recurrence after complete surgical resection, according to Bristol-Myers Squibb (BMS), the company that makes the drug.

Seven-year cancer survivor shares tips to help you get through cancer.

Merrick I. Ross, M.D., discussed key issues in melanoma as the treatment paradigm continues to change.